Last reviewed · How we verify
NCT05950087
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
trial testing Concurrent chemoradiotherapy in Locally Advanced Cervical Cancer in 30 participants. Currently enrolling.
30 November 2024
Quick facts
| Lead sponsor | Guizhou Provincial People's Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 November 2022 |
| Primary completion | 30 November 2024 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Concurrent chemoradiotherapy — full drug profile →
Conditions studied
- Locally Advanced Cervical Cancer — all drugs for Locally Advanced Cervical Cancer →
Sponsor
Guizhou Provincial People's Hospital
Who can join
Adults 18 to 75, female only, with Locally Advanced Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0 -
The clinical application value of dynamic monitoring of HPV ctDNA in concurrent chemoradiotherapy for locally advanced cervical cancer.
Zhang H, Luo X, Jiang J, Zhang C, et al · · 2026 · PMID 41776327 · DOI 10.1038/s41698-026-01348-7 -
Study on the efficacy and prognostic value of minimal residual disease in locally advanced cervical cancer based on plasma HPV-ctDNA protocol
Zhang C, Jiang J, Li L, Yang C, et al · · 2024 · DOI 10.21203/rs.3.rs-4519629/v1
Verify or expand the search:
- PubMed search for NCT05950087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Concurrent chemoradiotherapy
Trials testing the same drug.
- NCT06048926 — Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma · NA · enrolling by invitation
Other recruiting trials for Locally Advanced Cervical Cancer
Currently open trials in the same condition.
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
- NCT07055399 — Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) · Phase 2 · recruiting
- NCT06943833 — A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) · Phase 2 · active not recruiting
- NCT07205497 — QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer · Phase 2 · active not recruiting
- NCT07104149 — Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer · Phase 2 · recruiting
Other Guizhou Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07446686 — Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-R · EARLY_PHASE1 · not yet recruiting
- NCT06075290 — the Difference of Follow-up Methods of Neonatal Jaundice · unknown
- NCT05980520 — Study on the Treatment of Taurine in Children With Autism · NA · completed
- NCT05309174 — The Study of Bilateral Upper Laryngeal Nerve Block for Supporting the Removal of Vocal Cord Polyps Under Laryngoscopy · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05950087 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guizhou Provincial People's Hospital
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05950087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing